• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Eupraxia Pharmaceuticals Inc.

    11/8/24 11:49:54 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $EPRX alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001581178
    Plaza Capital Partners Inc.
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    EUPRAXIA PHARMACEUTICALS INC.
    Jurisdiction of Incorporation/Organization
    BRITISH COLUMBIA, CANADA
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    EUPRAXIA PHARMACEUTICALS INC.
    Street Address 1 Street Address 2
    201-2067 CADBORO BAY RD.
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    VICTORIA BRITISH COLUMBIA, CANADA V8R 5G4 250-590-3968

    3. Related Persons

    Last Name First Name Middle Name
    Helliwell James
    Street Address 1 Street Address 2
    201-2067 Cadboro Bay Road
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8R 5G4
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Cousins Bruce
    Street Address 1 Street Address 2
    201-2067 Cadboro Bay Road
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8R 5G4
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Malone Amanda
    Street Address 1 Street Address 2
    201-2067 Cadboro Bay Road
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8R 5G4
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Brennan Paul
    Street Address 1 Street Address 2
    201-2067 Cadboro Bay Road
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8R 5G4
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Kowalski Mark
    Street Address 1 Street Address 2
    201-2067 Cadboro Bay Road
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8R 5G4
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Pimstone Simon
    Street Address 1 Street Address 2
    201-2067 Cadboro Bay Road
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8R 5G4
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Freedman Joseph
    Street Address 1 Street Address 2
    201-2067 Cadboro Bay Road
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8R 5G4
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Geyer Paul
    Street Address 1 Street Address 2
    201-2067 Cadboro Bay Road
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8R 5G4
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Glickman Richard
    Street Address 1 Street Address 2
    201-2067 Cadboro Bay Road
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8R 5G4
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Montalbano John
    Street Address 1 Street Address 2
    201-2067 Cadboro Bay Road
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8R 5G4
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Wilmink Michael
    Street Address 1 Street Address 2
    201-2067 Cadboro Bay Road
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8R 5G4
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Sarugaser Rahul
    Street Address 1 Street Address 2
    201-2067 Cadboro Bay Road
    City State/Province/Country ZIP/PostalCode
    Victoria BRITISH COLUMBIA, CANADA V8R 5G4
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2024-10-31    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
       Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $1,894,413 USD
    or    Indefinite
    Total Amount Sold $1,894,413 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    U.S. dollar amounts are based on the Bank of Canada average rate of exchange reported on October 31, 2024, which was CDN$1.3916=US$1.00.

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    6

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    EUPRAXIA PHARMACEUTICALS INC. /s/Bruce Cousins Bruce Cousins President and Chief Financial Officer 2024-11-06

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $EPRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EPRX

    DatePrice TargetRatingAnalyst
    7/24/2025$11.00Overweight
    Cantor Fitzgerald
    6/26/2025$12.00Buy
    H.C. Wainwright
    6/16/2025Speculative Buy
    Canaccord Genuity
    2/21/2025$12.00Buy
    Craig Hallum
    11/14/2024$9.00Buy
    Rodman & Renshaw
    More analyst ratings

    $EPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Eupraxia Pharmaceuticals with a new price target

    Cantor Fitzgerald initiated coverage of Eupraxia Pharmaceuticals with a rating of Overweight and set a new price target of $11.00

    7/24/25 7:27:25 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    H.C. Wainwright initiated coverage on Eupraxia Pharmaceuticals with a new price target

    H.C. Wainwright initiated coverage of Eupraxia Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    6/26/25 8:10:08 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Canaccord Genuity initiated coverage on Eupraxia Pharmaceuticals

    Canaccord Genuity initiated coverage of Eupraxia Pharmaceuticals with a rating of Speculative Buy

    6/16/25 11:20:22 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    SEC Filings

    View All

    SEC Form S-8 filed by Eupraxia Pharmaceuticals Inc.

    S-8 - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

    2/4/26 9:12:31 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

    6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

    1/8/26 12:02:17 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Eupraxia Pharmaceuticals Inc.

    SCHEDULE 13G/A - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

    11/14/25 4:37:06 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy

    At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health1.At lower doses, patients maintained the improvements in tissue health1 reported at week 12 out until week 36. Clinical remission2 was achieved by 8 weeks and maintained through 52 weeks in the majority of patients for which more than 60% of their esophagus was treated.EP-104GI continues to be well tolerated by patients receiving the drug; over 200 patient-months of follow-up have been reported with no Serious Adverse Events ("SAEs"), and no cases of oral candidiasis. VICTORIA, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pha

    1/8/26 7:34:11 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI

    The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported from Cohort 5; Cohorts 5 & 6 are the only groups to reach 52 weeks thus far.In Cohort 6, a durable clinical symptom response was observed 52 weeks after a single administration of EP-104GI.All 3 patients in Cohort 6 maintained a clinical benefit and 2 out of 3 patients remain in clinical remission 52 weeks after treatment of EoE with EP-104GI.In combination with patients from Cohort 5, at 52 weeks, 4 out of 6 patients remain in clinical remission.At week 36, 67% of all patients in the trial that were measured at 36 weeks, were in clinical remission (Cohorts 5-7, n=9).O

    11/13/25 5:00:00 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

    Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026 Completed $80.5 million public offering supported by leading life science investors Cash runway to fund pipeline development and operations into the first half of 2028 VICTORIA, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet ne

    11/4/25 4:39:26 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Financials

    Live finance-specific insights

    View All

    Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

    Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in H2 2026Announced positive data from Phase 1b/2a RESOLVE supporting the potential of EP-104GI to improve the standard of care for patients with Eosinophilic Esophagitis ("EoE")Additional data from cohorts 5–8 from Phase 1b/2a available in October 2025 VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with

    8/12/25 4:25:54 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

    Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third quarter of 2026 Company to host webinar to discuss updated data from the RESOLVE trial on May 9th VICTORIA, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the first quar

    5/6/25 6:00:00 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

    VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "During the fourth quarter of 2024, and again in the current quarter of 2025, we delivered compelling data from our Phase 1b/2a RESOLVE trial for EP-

    3/20/25 5:30:48 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Eupraxia Pharmaceuticals Inc.

    SC 13G - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

    11/14/24 4:17:44 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form SC 13D filed by Eupraxia Pharmaceuticals Inc.

    SC 13D - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

    11/7/24 4:10:15 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Leadership Updates

    Live Leadership Updates

    View All

    Eupraxia Pharmaceuticals Announces CFO Succession

    -  Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role VICTORIA, BC, Feb. 18, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer, effective immediately. Bruce Cousins, the Company's outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities. "Having previously served as Eupraxia's CFO

    2/18/25 7:00:00 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

    VICTORIA, BC, Oct. 31, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, is pleased to announce that it has completed a non-brokered private placement of 8,905,638 Series 1 Preferred shares of the Company (the "Preferred Shares"), at a price of C$5.00 per Preferred Share for aggregate gross proceeds of C$44,528,190, by way of a non-brokered private placement (the "Private Placement").

    10/31/24 7:36:00 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care